2022 August 30, Ricardo Ruiz-Villaverde, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, Manuel Galan-Gutierrez, “Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain)”, in Journal of Clinical Medicine, volume 11, number 17, page 5